Supplementary Materials

Table S1. The diagnostic assessment of IgG and IgM ELISA tests with RT-PCR at the three-time intervals (≤14, 14-30, >30 days) and in symptomatic/asymptomatic COVID-19 patients (n=291).

Diagnostic assessment	IgG ELISA					IgM ELISA			
	EDI	**NovaLisa**	**AnshLabs**	**DiaPro**	**Lionex**	**EDI**	**NovaLisa**	**AnshLabs**	**Lionex**
Sensitivity **≤14** DPSO/DPD[1]	**49.6%** (59/119, 40.6-58.6)	**61.0%** (61/100, 51.4-70.6)	**78.2%** (93/119, 70.7-85.6)	**48.7%** (58/119, 39.8-57.7)	**58.6%** (58/99, 48.9-68.3)	**48.7%** (58/119, 39.8-57.7)	**46.2%** (55/119, 37.3-55.2)	**53.8%** (64/119, 44.8-62.8)	**66.4%** (79/119, 57.9-74.9)
Sensitivity **14-30** DPSO/DPD[1]	**61.8%** (34/55, 49.0-74.7)	**81.5%** (44/54, 71.1-91.8)	**83.6%** (46/55, 73.9-93.4)	**60.0%** (33/55, 47.1-72.9)	**81.5%** (44/54, 71.1-91.8)	**34.5%** (20/55, 22.0-47.1)	**29.1%** (16/55, 17.1-41.1)	**38.2%** (21/55, 25.3-51.0)	**61.8%** (34/55, 49.0-74.7)
Sensitivity **>30** DPSO/DPD[1]	**76.1%** (89/117, 68.3-83.8)	**90.0%** (99/110, 84.4-95.6	**95.7%** (112/117, 92.1-99.4)	**53.5%** (38/71, 41.9-65.1)	**96.6%** (113/117, 93.3-99.9)	**10.3%** (12/117, 4.8-15.8)	**12.8%** (15/117, 6.8-18.9)	**6.8%** (8/117, 2.3-11.4)	**47.9%** (56/117, 38.8-56.9)
Sensitivity in **symptomatic** COVID-19 patients	**71.4%** (104/147, 64.1-78.7)	**84.1%** (111/132, 77.9-90.3)	**89.1%** (131/147, 84.1-94.2)	**67.3%** (99/147, 59.8-74.9)	**84.1%** (111/132, 77.9-90.3)	**52.4%** (77/147, 44.3-60.5)	**45.6%** (67/147, 37.5-53.6)	**57.1%** (84/147, 49.1-65.1)	**75.5%** (111/147, 68.6-82.5)
Sensitivity in **asymptomatic** COVID-19 patients	**56.0%** (65/116, 47.0-65.1)	**67.9%** (74/109, 59.1-76.7)	**86.2%** (100/116, 79.9-92.5)	**24.3%** (18/70, 14.2-34.3)	**71.6%** (83/116, 63.3-79.8)	**7.8%** (9/116, 2.9-12.6)	**13.8%** (16/116, 7.5-20.1)	**3.4%** (4/116, 0.13-6.8)	**39.7%** (46/116, 30.8-48.6)
Overall sensitivity	**62.5%** (182/291, 57.0-68.1)	**77.6%** (204/263, 72.5-82.6)	**86.3%** (251/291, 82.3-90.2)	**52.7%** (129/245, 46.4-58.9)	**80.0%** (216/270, 75.2-84.8)	**30.6%** (89/291, 25.3-35.9)	**29.6%** (86/291, 24.3-34.8)	**31.6%** (92/291, 26.3-37.0)	**58.4%** (170/291, 52.8-64.1)
Overall agreement with RT-PCR	**72.9%** (68.6-77.2)	**83.5%** (79.8-87.2)	**85.6%** (82.2-89.0)	**60.2%** (55.1-65.2)	**85.3%** (81.8-88.9)	**50.5%** (45.6-55.3)	**46.8%** (42.0-51.7)	**50.0%** (45.2-54.8)	**67.1%** (62.5-71.6)
Positive predictive value	**98.9%** (97.9-99.9)	**98.1%** (96.7-99.5)	**93.0%** (90.5-95.4)	**81.6%** (77.6-85.6)	**98.6%** (97.5-99.8)	**98.9%** (97.8-99.9)	**86.9%** (83.6-90.1)	**93.9%** (91.6-96.2)	**92.4%** (89.8-94.9)
Negative predictive value	**51.8%** (46.9-56.6)	**66.1%** (61.3-70.8)	**71.4%** (67.1-75.8)	**43.7%** (38.6-48.8)	**68.2%** (63.6-72.9%)	**36.9%** (32.2-41.5)	**34.1%** (29.5-38.7)	**36.2%** (31.6-40.9)	**46.5%** (41.6-51.3)

[1]DPSO: Days post symptoms onset, DPD: days post diagnosis

Figure S1. Assays sensitivity according to time of sampling after symptoms onset or positive SARS-CoV-2 RT-PCR test from only symptomatic COVID-19 patients. Chi-square test was used to detect the presence of a statistically significant difference in the sensitivity between the time intervals in each assay.